Sandoz To Acquire Aspen’s Japanese Operations
Up to €400m Deal Strengthens Hospitals Portfolio
Sandoz is to pay up to €400m for Aspen’s anesthetics and other specialty off-patent brands in Japan, strengthening the Novartis division’s local position in the hospitals market.
You may also be interested in...
Teva has announced a major strategic shift in Japan, with its Teva Takeda Pharma joint venture striking a deal to divest the majority of its traditional generics business to Nichi-Iko so that it can focus instead on complex generics and specialty products.
Having benefited financially from the increased demand from the coronavirus pandemic in the first quarter, Sandoz saw a reversal of fortune in Q2 as sales fell by more than one-tenth as reported, as the company explained to Generics Bulletin.
Sandoz says closing the door on its proposed deal with Aurobindo will open up opportunities for the Novartis subsidiary to optimize its US business, as global sales for Sandoz shot up by around a tenth in the first quarter of 2020 on the back of a COVID-19 boost and a leap of almost a third in Biopharmaceuticals sales.